VRP Stream Log

Hardman update: "VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which has de-risked RPL554 significantly. This drug has been shown to have strong bronchodilatory and anti-inflammatory effects with minimal side effects. New funds will support a broad programme of Phase II trials for maintenance therapy via a nebulizer and hospital use. It will certainly attract the attention of the drug majors." taken from research tree

"Verona Pharma is at an exciting stage of its development with a new proprietary suspension formulation of its first-in-class RPL554. The proposed £44.7m equity capital raise announced Friday, supported by group of US and EU healthcare focused funds, enables the group to progress its development of RPL554 through to a Phase III ready stage. If development goes according to plan, RPL554 could be in a position to commence Phase III trials by the end of 2018." N+1 Singer's note out this morning on Research Tree

share never go up in straight lines, take the dip as an opportunity to buy. this stock will be 5p year end.

Welcome to the new Verona Pharma stream forum! Messages posted in the Verona Pharma stream will be logged here for posterity.